Marrow-stimulation for focal chondral defects — awl perforation, super-clot formation, and the biology of fibrocartilage repair
Microfracture succeeds or fails largely on patient and lesion selection, decided long before the awl ever touches bone. Arthroscopic assessment characterizes defect size, depth, containment, and the quality of the surrounding cartilage rim, while patient factors — age, activity level, alignment, and time since injury — determine whether the biological repair this procedure produces will actually hold up under load.
Microfracture is a first-line, single-stage marrow-stimulation procedure best suited to a fairly narrow indication window:
• Defect size: classically <2–4 cm², typically on the femoral condyle. Larger defects can be treated, but fill quality and durability drop substantially as area increases — this is one of the most consistent findings across the microfracture literature. • Defect type: isolated, focal, full-thickness (International Cartilage Repair Society Grade III–IV) chondral defects with bone loss limited to the subchondral plate — not composite osteochondral defects with major bone loss (those need bone grafting, not marrow stimulation alone). • Patient age: outcomes are consistently better under ~40 years old, reflecting both higher chondrogenic potential of marrow-derived mesenchymal stem cells (MSCs) and lower background of degenerative change elsewhere in the joint. • Alignment and stability: concomitant malalignment (varus/valgus), ligament insufficiency, or menial deficiency must be corrected — an unstable or overloaded joint will mechanically overwhelm the fragile new repair tissue regardless of how well the marrow-stimulation itself is performed. • Activity demand: appropriate for patients who can adhere to a lengthy, disciplined rehabilitation protocol — the biology is unforgiving of early overload.
Once the joint is entered arthroscopically, the surgeon systematically probes the defect and its margins:
• Sizing: the defect is measured directly with a calibrated probe; surface area is recorded for the operative note and heavily influences prognosis. • Rim assessment: the surrounding cartilage is probed for delamination — any loose or undermined cartilage at the shoulder of the defect is unstable and must be debrided back to firmly attached tissue, leaving a vertical, stable wall. A defect with feathered, unstable edges will progressively enlarge under a fibrocartilage patch that cannot bear the same shear loads as native tissue. • Calcified cartilage layer: the thin, mineralized tidemark layer at the base of the defect is removed with a curette, exposing the true subchondral bone plate. Leaving this layer in place is a recognized technical error — it can block the marrow clot from properly integrating with the defect base and is associated with inferior fill and integration in comparative studies. • Subchondral bone quality: the surgeon confirms bone stock is adequate — sclerotic, eburnated, or deficient bone changes the calculus and may favor an osteochondral or bone-grafting approach instead.
Defect size is the single strongest predictor of long-term microfracture outcome in the clinical literature. Lesions under roughly 2 cm² reliably do well; each additional cm² erodes both fill quality and durability, which is why microfracture is now framed as a small-defect, first-line option rather than a universal cartilage solution.
The procedure that gives this technique its name is deceptively simple: a surgeon uses an angled arthroscopic awl to punch a controlled grid of small holes through the exposed subchondral bone plate. The apparent simplicity conceals real technical nuance — perforation spacing, depth, and instrument choice all measurably affect the marrow access, and therefore the repair tissue, that follows.
With the defect debrided to a stable rim and the calcified cartilage layer removed, the surgeon systematically perforates the exposed subchondral plate:
• Starting point: perforations typically begin at the periphery of the defect, adjacent to the stable cartilage rim, and work inward — this ensures even coverage and avoids missing the margins where fibrocartilage integration with native tissue matters most. • Spacing: holes are placed roughly 3–4 mm apart, edge to edge. This spacing is a deliberate compromise — closer spacing risks perforations coalescing and fracturing the intervening bone bridges (compromising the structural plate that supports the new tissue); wider spacing leaves gaps with poor marrow access and patchy fill. • Depth: the awl is advanced only 2–4 mm into the underlying cancellous bone — just enough to breach into the marrow space and produce free bleeding, without excessively destabilizing the subchondral plate architecture that will support the maturing repair tissue. • Verification: adequate perforation is confirmed visually — fat droplets and blood should be seen welling from each hole once the arthroscopic fluid pressure is reduced, confirming that the marrow cavity has genuinely been accessed rather than just superficially scored.
Two instruments can create the perforations: a manually-driven angled awl, or a powered drill bit.
• Thermal necrosis risk: drilling generates frictional heat at the bone interface. Even modest thermal injury to the surrounding cancellous bone can kill adjacent osteocytes and bone marrow elements, reducing the pool of viable MSCs available to populate the clot and potentially altering the local bone architecture. The awl, driven by hand pressure rather than rotation, avoids this heat generation entirely. • Structural disruption: drilling can also compact and glaze the bony walls of the perforation tunnel, effectively sealing off some of the marrow channels it was meant to open — an awl tends to fracture bone open cleanly rather than compacting it. • Practical trade-off: the awl requires more hand strength and can be technically harder to angle correctly in tight or posterior compartments of the joint, which is why some surgeons reserve drilling for difficult-access lesions despite its theoretical downsides.
Because of the thermal-necrosis concern, the manual awl remains the technique originally described by Steadman et al. and is still generally preferred whenever access allows.
At the conclusion of perforation, the defect base is transformed from a smooth, avascular, sclerotic bone surface into a porous field studded with a grid of small channels actively welling blood and marrow fat. Arthroscopic fluid inflow is turned down or off specifically to allow this bleeding to be visually confirmed before the case is finished — a dry defect base means inadequate perforation and a high risk of poor healing. This bleeding marrow is the entire biological premise of the procedure: over the following minutes to hours, it organizes into the clot that will become the actual repair tissue.
This stage is the biological heart — and central limitation — of microfracture. The perforations release marrow elements that clot and organize into repair tissue, but that tissue is fibrocartilage, not the native hyaline cartilage it is replacing. Understanding exactly how these two tissues differ, at the molecular and mechanical level, explains virtually everything about microfracture's clinical strengths and its well-documented long-term weaknesses.
The moment the subchondral plate is perforated, several marrow-derived elements pour into the debrided defect and combine:
• Mesenchymal stem cells (MSCs): multipotent progenitor cells resident in bone marrow, capable of differentiating along chondrogenic, osteogenic, or fibroblastic lineages depending on the local mechanical and biochemical environment. • Growth factors and cytokines: platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), bone morphogenetic proteins (BMPs), and others are released from degranulating platelets and the marrow itself, providing signals that drive cell recruitment, proliferation, and early differentiation. • Blood and fibrin: whole blood clots within the debrided, contained defect, forming a fibrin scaffold that traps the MSCs and growth factors in place rather than letting them wash away in joint fluid.
This combination — sometimes called the "super-clot" — is the entire regenerative substrate for what follows. Its quality depends directly on the perforation technique from Stage 2: adequate density, depth, and bleeding all increase the volume and cellularity of the clot that forms.
Over the following weeks, the super-clot organizes and its resident MSCs differentiate — but critically, under the mechanical and biochemical conditions present in an open joint defect, this differentiation predominantly yields fibrocartilage rather than native hyaline cartilage:
• Native hyaline articular cartilage: composed predominantly of type II collagen arranged in a highly organized, zonal architecture (tangential zone at the surface, transitional and radial zones deeper), embedded in a proteoglycan-rich matrix (aggrecan) that gives it exceptional resistance to compressive load and low-friction gliding properties. This architecture takes an embryological developmental program to build — it is not simply recreated by an adult wound-healing response. • Fibrocartilage repair tissue: composed predominantly of type I collagen (the collagen type typical of scar tissue, tendon, and fibrous tissue generally) with a disorganized fiber arrangement and a lower, less-organized proteoglycan content. Some type II collagen and organized architecture can appear at the tissue's periphery in favorable cases, but the bulk of microfracture repair tissue remains fibrocartilaginous.
This type I vs. type II collagen distinction is the fundamental biological limitation of marrow stimulation: the tissue formed is a biological patch, not a biological restoration.
Fibrocartilage's inferior compressive stiffness and durability compared to native hyaline cartilage is not a minor technical detail — it is the central reason microfracture outcomes tend to deteriorate over time under sustained mechanical loading, particularly in larger defects or high-demand patients. Every downstream stage of this simulation — rehabilitation protocol, outcome durability — traces back to this single biological fact.
Fibrocartilage formation follows a roughly predictable, if biologically variable, timeline:
• Weeks 0–2: fibrin clot stabilizes within the defect; early MSC proliferation begins. • Weeks 2–8: clot is progressively replaced by a mesenchymal, fibroblast-rich tissue; early matrix deposition (largely type I collagen) begins to fill the defect volume. • Months 2–6: matrix remodeling and progressive mechanical maturation of fibrocartilage; tissue is still relatively soft and vulnerable to shear/impact loading during this period. • Months 6–12+: repair tissue reaches its maximum maturity and mechanical properties for that individual defect — properties that, even at their peak, remain inferior to native hyaline cartilage and that tend to be most durable in the smallest, best-contained defects.
Because the repair tissue forming inside the defect is biologically fragile and mechanically weak in its early weeks, the postoperative rehabilitation protocol is not an afterthought — it is arguably as important to the ultimate outcome as the perforation technique itself. Continuous passive motion and a carefully staged weight-bearing progression exist specifically to nurture the clot into well-oriented, well-integrated fibrocartilage while protecting it from forces it cannot yet withstand.
Continuous passive motion (CPM) is a mechanized device that slowly and repeatedly flexes and extends the joint through a controlled arc of motion, without the patient generating any muscular force or bearing weight. In microfracture rehabilitation it plays a specific biological role:
• Mechanical stimulation without load: cyclical, low-shear motion is believed to promote nutrient and oxygen diffusion into the avascular joint space, support even distribution of the marrow clot across the defect surface, and provide the kind of gentle mechanical signaling that favors chondrogenic (cartilage-like) differentiation of the resident MSCs over pure fibrous/scar differentiation. • Protocol: CPM is typically started within the first 1–2 postoperative days and used for several hours per day (often prescribed in the range of 6–8 hours total, split across sessions) for a period of weeks, with the arc of motion gradually increased as tolerated. • Contrast with immobilization: earlier surgical eras sometimes immobilized joints after cartilage procedures; animal and clinical data instead support early controlled motion — immobilized defects tend to fill with tissue that is more disorganized and mechanically inferior than tissue exposed to early CPM.
While CPM manages motion, weight-bearing restriction manages compressive and shear load — the forces most capable of physically disrupting an immature clot before it has organized and adhered to the defect base:
• Immediate postoperative period (0–6/8 weeks): weight-bearing is typically restricted to toe-touch or partial weight-bearing with crutches, particularly for femoral condyle and other primary weight-bearing surface lesions. Patellofemoral lesions may tolerate earlier loading in some protocols since axial load is less directly transmitted, but flexion-based loading is still restricted. • Progressive loading (roughly weeks 6–12): weight-bearing is gradually advanced from partial to full as tolerated, guided by pain, effusion, and time-based milestones rather than by imaging (which cannot reliably confirm fibrocartilage maturity at this stage). • Strengthening phase (roughly months 3–6): closed-chain strengthening, stationary cycling, and low-impact conditioning are introduced and progressed; higher-impact activities remain restricted. • Return to sport/impact loading (commonly 4–6 months or later): only after functional strength, range of motion, and absence of effusion/pain criteria are met — and often later still for larger defects or less predictable healing, since the tissue's mechanical ceiling is inherently lower than native cartilage.
The rehabilitation timeline exists to match mechanical demand to the maturing repair tissue's actual load tolerance at each point in time — loading too early is one of the most commonly cited, and most preventable, causes of poor microfracture outcomes.
Decades of clinical follow-up have produced a consistent picture: microfracture reliably delivers good pain relief and functional improvement in the short-to-medium term, especially in well-selected small defects — but a substantial fraction of patients show measurable deterioration within roughly two to five years, tracking the known mechanical inferiority of fibrocartilage. This pattern has reshaped how microfracture is positioned in the modern cartilage-repair treatment algorithm.
A large and fairly consistent body of clinical follow-up literature describes a two-phase outcome pattern after microfracture:
• Phase 1 — early benefit (roughly year 1–2): most well-selected patients, particularly with small defects, report significant improvement in pain and function versus their preoperative baseline, often comparable in the short term to more complex, more expensive cartilage procedures. • Phase 2 — decline (roughly years 2–5 and beyond): a substantial subset of patients show progressive worsening of clinical scores, and imaging/second-look arthroscopy frequently demonstrates thinning, fissuring, or incomplete fill of the fibrocartilage repair tissue during this window.
This is not considered a technical failure of the index procedure so much as an expected consequence of the underlying biology: fibrocartilage simply does not possess the durability of native hyaline cartilage under years of repetitive joint loading, and it gradually wears in a way native cartilage — or a hyaline-like repair — would resist far longer.
Across studies, defect size is repeatedly identified as one of the strongest — if not the strongest — predictors of long-term microfracture durability:
• Small defects (roughly <2 cm²): tend to show the best fill quality, the most durable clinical improvement, and the lowest rates of subsequent revision surgery. • Medium defects (roughly 2–4 cm²): outcomes become progressively less reliable; a meaningful proportion of patients still deteriorate within the 2–5 year window. • Large defects (>4 cm²): microfracture alone is now generally discouraged as primary treatment — fill is often incomplete, mechanical demand per unit of repair tissue is higher, and failure rates climb substantially.
This size-dependence is intuitive given the underlying biology: a larger area of unsupported, mechanically inferior fibrocartilage is simply less able to withstand joint loading than a small, well-contained patch surrounded by supportive native cartilage.
Given this durability profile, microfracture has been increasingly repositioned within the broader cartilage-repair treatment algorithm rather than abandoned:
• First-line, lower-cost option for small defects: microfracture remains attractive precisely because it is a single-stage, arthroscopic, comparatively inexpensive procedure with low morbidity — well matched to small, well-contained lesions where its durability limitations are least consequential. • Reserved role after failure or for larger lesions: autologous chondrocyte implantation (ACI, including matrix-induced variants) and osteochondral autograft/allograft transfer (OATS/mosaicplasty) are generally preferred for larger defects, or as a secondary procedure after microfracture has already failed — both approaches aim to restore more hyaline-like cartilage or transplant native hyaline cartilage directly, at the cost of greater surgical complexity, staging, and expense. • Emerging refinements: some centers now augment microfracture with scaffolds, platelet-rich plasma, or other biologic adjuncts intended to improve clot retention and steer differentiation toward a more hyaline-like phenotype, though these remain adjuncts to — not replacements for — the fundamental marrow-stimulation principle described in this simulation.
The modern consensus frames microfracture not as a universal cartilage cure, but as a well-defined tool: excellent for small, well-contained defects in appropriately selected patients who will respect the rehabilitation protocol, and a reasonable first step before committing to the greater cost and complexity of cell-based or osteochondral graft techniques for larger or recurrent lesions.